Neurobiology of Disease

Mosaic and non-mosaic protocadherin 19 mutation leads to neuronal hyperexcitability in zebrafish.  169. 2022

Striatal Synaptic Dysfunction in Dystonia and Levodopa-Induced Dyskinesia.  166. 2022

Corrigendum to “α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration” [Neurobiol. Dis., Volume 105 (2017) Article 84, 98](S0969996117301201)(10.1016/j.nbd.2017.05.014).  159. 2021

Dysregulated clock gene expression and abnormal diurnal regulation of hippocampal inhibitory transmission and spatial memory in amyloid precursor protein transgenic mice.  158. 2021

The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.  153. 2021

Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats.  150. 2021

Effects of exercise on sleep in neurodegenerative disease.  140. 2020

A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity.  134. 2020

Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.  134. 2020

LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease.  134. 2020

Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?.  132. 2019

Multigenerational epigenetic inheritance: One step forward, two generations back.  132. 2019

Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.  125:146-153. 2019

Human and rodent temporal lobe epilepsy is characterized by changes in O-GlcNAc homeostasis that can be reversed to dampen epileptiform activity.  124:531-543. 2019

Pα-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria.  124:248-262. 2019

Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice.  124:152-162. 2019

TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: Molecular mechanisms, cellular processes, and emerging therapeutic opportunities..  122:83-93. 2019

Astrocyte-specific DJ-1 overexpression protects against rotenone-induced neurotoxicity in a rat model of Parkinson's disease.  115:101-114. 2018

Behavioral and SCN neurophysiological disruption in the Tg-SwDI mouse model of Alzheimer's disease.  114:194-200. 2018

Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis.  114:85-94. 2018

The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein.  110:68-81. 2018

Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.  109:249-257. 2018

Editorial: Pathogenic templating proteins in Neurodegenerative Disease.  109:175-177. 2018

Effects of α-synuclein on axonal transport.  105:321-327. 2017

α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration.  105:84-98. 2017

Dysregulation of BET proteins in levodopa-induced dyskinesia.  102:125-132. 2017

Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.  98:122-136. 2017

The neurobiology of HIV and its impact on cognitive reserve: A review of cognitive interventions for an aging population.  92:144-156. 2016

An altered peripheral IL6 response in major depressive disorder.  89:46-54. 2016

Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders.  85:254-261. 2016

Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.  79:1-13. 2015

Differential proteomic and behavioral effects of long-term voluntary exercise in wild-type and APP-overexpressing transgenics.  78:45-55. 2015

Hyperactivity and cortical disinhibition in mice with restricted expression of mutant huntingtin to parvalbumin-positive cells.  62:160-171. 2014

Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.  70:190-203. 2014

Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.  62:113-123. 2014

Cuprizone short-term exposure: astrocytic IL-6 activation and behavioral changes relevant to psychosis..  59:63-68. 2013

Enhanced Ca²⁺-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model.  58:192-199. 2013

MicroRNA-382 expression is elevated in the olfactory neuroepithelium of schizophrenia patients..  55:1-10. 2013

RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.  54:264-279. 2013

Neurodevelopmental impairment following neonatal hyperoxia in the mouse.  50:69-75. 2013

Preferential inactivation of SCN1A in parvalbumin interneurons increases seizure susceptibility.  49:211-220. 2013

Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA.  47:416-427. 2012

8OHdG as a marker for Huntington disease progression.  46:625-634. 2012

Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity.  43:79-85. 2011

Update on the pathology of dystonia.  42:148-151. 2011

Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and Ataxia.  41:11-22. 2011

Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.  40:531-543. 2010

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.  40:73-81. 2010

Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia.  38:434-445. 2010

Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention.  37:510-518. 2010

VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease.  37:330-338. 2010

Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.  35:219-233. 2009

Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease.  34:525-534. 2009

Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations.  34:199-211. 2009

Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia.  34:133-145. 2009

Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology.  34:163-177. 2009

Decreased glutamate transport enhances excitability in a rat model of cortical dysplasia.  32:254-261. 2008

Transcriptional dysregulation in a transgenic model of Parkinson disease.  29:515-528. 2008

Effects of gender on nigral gene expression and parkinson disease.  26:606-614. 2007

Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia.  24:318-325. 2006

Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease.  24:280-285. 2006

Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.  23:502-511. 2006

Deposition of mouse amyloid β in human APP/PS1 double and single AD model transgenic mice.  23:653-662. 2006

Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.  20:656-665. 2005

Red cell interactions with amyloid-β1-40 fibrils in a murine model.  19:28-37. 2005

Erratum: Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice (Neurobiology of Disease (2003) 14 (318-327) DOI: 10.1016/j.nbd.2003.08.009).  16:290. 2004

Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: Analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation.  14:624-636. 2003

DNA microarray analysis of functionally discrete human brain regions reveals divergent transcriptional profiles.  14:240-250. 2003

Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice.  14:318-327. 2003

TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion.  12:11-24. 2003

Cellular distribution of NMDA glutamate receptor subunit mRNAs in the human cerebellum.  4:35-46. 1997

Huntington’s disease cag trinucleotide repeats in pathologically confirmed post-mortem brains.  1:159-166. 1994